Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ABHIJEET KUMAR

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1134409923
CMS profile
2786418
Location
BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$45,295.95

54 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Incyte Corporation $28,119.38 31
AstraZeneca Pharmaceuticals LP $14,141.19 10
ABBVIE INC. $2,958.94 9
PFIZER INC. $33.76 2
Geron Corporation $22.68 1
Tempus AI, Inc $20.00 1

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ABHIJEET KUMAR

NPI 1134409923 · CMS profile ID 2786418

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

BALTIMORE, MD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134409923?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ABHIJEET KUMAR, NPI 1134409923, CMS profile ID 2786418. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134409923?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ABHIJEET KUMAR, NPI 1134409923, CMS profile ID 2786418. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134409923?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ABHIJEET KUMAR, NPI 1134409923, CMS profile ID 2786418, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1134409923?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

54 matching records · $45,295.95 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 54 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–54 of 54.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Tempus AI, Inc $20.0004/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1250347906 CMS
AstraZeneca Pharmaceuticals LP $21.2804/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206842997 CMS
Geron Corporation $22.6802/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238890286 CMS
PFIZER INC. $18.2901/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230213305 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,990.53 10
PY2020 $1,875.52 12
PY2023 $37.40 1
PY2024 $15,068.64 21
PY2025 $45,295.95 54

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $393,692.84 168
PY2024 Principal investigator $567,698.85 161
PY2023 Principal investigator $382,710.87 143
PY2022 Principal investigator $306,571.10 127
PY2021 Principal investigator $82,080.35 60
PY2020 Principal investigator $218,560.38 143
PY2019 Principal investigator $163,209.44 87

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

168 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
NORTH CAMPUS PHARMACY RECIEVING
A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies No dispute reported 06/30/2026 1202535275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,641.70 12/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184278810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,288.70 12/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184278812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.00 12/11/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184274262
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $910.00 12/11/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184274264
Principal investigator 1 BeOne Medicines USA, Inc. $1,430.00 12/09/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190328889
Principal investigator 1 BeOne Medicines USA, Inc. $1,516.00 12/09/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333086
Principal investigator 1 ABBVIE INC. $3,413.59 12/08/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202529664
Principal investigator 1 Epizyme, Inc. $999.50 12/08/2025 Non-covered Recipient Entity
University Arizona Cancer Ctr
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282753
Principal investigator 1 Epizyme, Inc. $1,000.00 12/08/2025 Non-covered Recipient Entity
University Arizona Cancer Ctr
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282755
Principal investigator 1 Epizyme, Inc. $1,250.00 12/08/2025 Non-covered Recipient Entity
University Arizona Cancer Ctr
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282757
Principal investigator 1 ABBVIE INC. $539.50 12/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202528106
Principal investigator 1 ABBVIE INC. $1,144.00 12/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202526240
Principal investigator 1 ABBVIE INC. $3,413.59 11/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202525392
Principal investigator 1 BeOne Medicines USA, Inc. $1,430.00 11/25/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190328891
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,515.50 11/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184263407
Principal investigator 1 BeOne Medicines USA, Inc. $1,170.00 11/18/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190328885
Principal investigator 1 BeOne Medicines USA, Inc. $975.00 11/18/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190328887
Principal investigator 1 BeOne Medicines USA, Inc. $975.00 11/18/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190328893
Principal investigator 1 ABBVIE INC. $4,420.00 11/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202520105
Principal investigator 1 ABBVIE INC. $52.00 10/31/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202519961
Principal investigator 1 Epizyme, Inc. $128.70 10/31/2025 Non-covered Recipient Entity
University Arizona Cancer Ctr
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282749
Principal investigator 1 ABBVIE INC. $2,470.00 10/30/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202519827
Principal investigator 1 ABBVIE INC. $780.00 10/28/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202518815
Principal investigator 1 BeOne Medicines USA, Inc. $1,720.00 10/28/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333082
Principal investigator 1 ABBVIE INC. $1,755.00 10/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202518397
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $123.50 10/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184252464
Principal investigator 1 ABBVIE INC. $39,355.61 10/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202518185
Principal investigator 1 ABBVIE INC. $1,105.00 10/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202517453
Principal investigator 1 Epizyme, Inc. $850.00 10/20/2025 Non-covered Recipient Entity
University Arizona Cancer Ctr
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184282751
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,264.60 10/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184248856
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,641.70 10/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184248858
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,268.60 10/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184248860
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,488.20 10/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184244525
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,112.20 10/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184244527
Principal investigator 1 ABBVIE INC. $5,560.94 09/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202512774
Principal investigator 1 BeOne Medicines USA, Inc. $3,106.00 09/23/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333070
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $71.50 09/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184241884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,641.70 09/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184241886
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,268.60 09/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184241888
Principal investigator 1 ABBVIE INC. $780.00 09/18/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202511490
Principal investigator 1 ABBVIE INC. $1,287.00 09/16/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202511038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,024.50 09/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184236866
Principal investigator 1 Epizyme, Inc. $1,630.00 09/11/2025 Non-covered Recipient Entity
Banner University Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184284548
Principal investigator 1 Epizyme, Inc. $750.00 09/04/2025 Non-covered Recipient Entity
Banner University Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184284542
Principal investigator 1 Epizyme, Inc. $1,000.00 09/04/2025 Non-covered Recipient Entity
Banner University Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184284544
Principal investigator 1 Epizyme, Inc. $1,200.00 09/04/2025 Non-covered Recipient Entity
Banner University Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184284546
Principal investigator 1 Epizyme, Inc. $4,986.25 09/04/2025 Non-covered Recipient Entity
Banner University Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184284550
Principal investigator 1 ABBVIE INC. $2,080.00 09/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202506947
Principal investigator 1 BeOne Medicines USA, Inc. $12,596.00 09/02/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190328895
Principal investigator 1 BeOne Medicines USA, Inc. $2,210.00 09/02/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190328897
Principal investigator 1 BeOne Medicines USA, Inc. $1,170.00 09/02/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190328899
Principal investigator 1 ABBVIE INC. $1,040.00 08/28/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202506429
Principal investigator 1 ABBVIE INC. $1,040.00 08/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202505855
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $780.00 08/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184230577
Principal investigator 1 Epizyme, Inc. $250.00 08/22/2025 Non-covered Recipient Entity
Banner University Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184284538
Principal investigator 1 Epizyme, Inc. $593.75 08/22/2025 Non-covered Recipient Entity
Banner University Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184284540
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,109.30 08/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184229891
Principal investigator 1 ABBVIE INC. $1,144.00 08/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202504983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 08/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184228569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,437.90 08/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184226477
Principal investigator 1 ABBVIE INC. $1,755.00 07/30/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202500522
Principal investigator 1 BeOne Medicines USA, Inc. $4,973.00 07/29/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333074
Principal investigator 1 Epizyme, Inc. $125.00 07/18/2025 Non-covered Recipient Entity
Banner University Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184284536
Principal investigator 1 ABBVIE INC. $650.00 07/17/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202498746
Principal investigator 1 ABBVIE INC. $1,105.00 07/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202498310
Principal investigator 1 ABBVIE INC. $1,040.00 07/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202497654
Principal investigator 1 BeOne Medicines USA, Inc. $3,840.00 07/07/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190333077
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $130.00 07/06/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804238
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $910.00 07/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184212717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $195.00 07/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184212719
Principal investigator 1 ABBVIE INC. $2,170.69 07/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202496217
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $260.00 06/20/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804236
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,221.10 06/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184209380
Principal investigator 1 ABBVIE INC. $845.00 06/18/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202492227
Principal investigator 1 ABBVIE INC. $780.00 06/18/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202492235
Principal investigator 1 ABBVIE INC. $3,584.81 06/17/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202491815
Principal investigator 1 ABBVIE INC. $2,470.00 06/17/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202491817
Principal investigator 1 ABBVIE INC. $780.00 06/17/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202491821
Principal investigator 1 ABBVIE INC. $507.00 06/17/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202491823
Principal investigator 1 BeOne Medicines USA, Inc. $2,860.00 06/17/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190331579
Principal investigator 1 BeOne Medicines USA, Inc. $175.00 06/17/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190331585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,502.30 06/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184204469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $780.00 06/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184204471
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 06/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184204473
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,900.00 06/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184204475
Principal investigator 1 ABBVIE INC. $4,485.00 06/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202488975
Principal investigator 1 ABBVIE INC. $4,191.88 06/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202488977
Principal investigator 1 BeOne Medicines USA, Inc. $9,842.99 05/30/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190326016
Principal investigator 1 BeOne Medicines USA, Inc. $780.00 05/30/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190331581
Principal investigator 1 BeOne Medicines USA, Inc. $2,210.00 05/30/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190331583
Principal investigator 1 BeOne Medicines USA, Inc. $975.00 05/30/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190331587
Principal investigator 1 BeOne Medicines USA, Inc. $390.00 05/30/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190331589
Principal investigator 1 BeOne Medicines USA, Inc. $455.00 05/30/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190331591
Principal investigator 1 ABBVIE INC. $2,080.00 05/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202487075
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $390.00 05/29/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804232
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $260.00 05/29/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804234
Principal investigator 1 ABBVIE INC. $819.00 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202486031
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $752.65 05/09/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804228
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,040.00 05/09/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804230
Principal investigator 1 ABBVIE INC. $249.60 05/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202481089
Principal investigator 1 ABBVIE INC. $1,924.00 04/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202479569
Principal investigator 1 ABBVIE INC. $780.00 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202479125
Principal investigator 1 ABBVIE INC. $325.00 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202479129
Principal investigator 1 ABBVIE INC. $845.00 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202479134
Principal investigator 1 ABBVIE INC. $123.50 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202479139
Principal investigator 1 ABBVIE INC. $975.00 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202479158
Principal investigator 1 ABBVIE INC. $1,040.00 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202479162
Principal investigator 1 ABBVIE INC. $2,080.00 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202479166
Principal investigator 1 ABBVIE INC. $2,080.00 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202479170
Principal investigator 1 ABBVIE INC. $1,144.00 04/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202478779
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $780.00 04/20/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804226
Principal investigator 1 ABBVIE INC. $1,828.79 04/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202471957
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,170.00 04/01/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804224
Principal investigator 1 ABBVIE INC. $780.00 03/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202466733
Principal investigator 1 ABBVIE INC. $325.00 03/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202466981
Principal investigator 1 ABBVIE INC. $780.00 03/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202465008
Principal investigator 1 ABBVIE INC. $507.00 03/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202465034
Principal investigator 1 ABBVIE INC. $1,040.00 03/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202465065
Principal investigator 1 Epizyme, Inc. $250.00 03/13/2025 Non-covered Recipient Entity
Banner University Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184284534
Principal investigator 1 BeiGene USA, Inc. $1,430.00 03/11/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190325868
Principal investigator 1 ABBVIE INC. $5,056.38 03/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202459975
Principal investigator 1 ABBVIE INC. $10,199.38 03/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202462164
Principal investigator 1 BeiGene USA, Inc. $302.00 03/04/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190324570
Principal investigator 1 BeiGene USA, Inc. $390.00 03/04/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190325870
Principal investigator 1 BeiGene USA, Inc. $780.00 03/04/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190325872
Principal investigator 1 Epizyme, Inc. $125.00 03/04/2025 Non-covered Recipient Entity
Banner University Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184284532
Principal investigator 1 Genmab BV $3,120.00 03/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. No dispute reported 06/30/2026 1235937496
Principal investigator 1 Genmab BV $3,900.00 03/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. No dispute reported 06/30/2026 1235937499
Principal investigator 1 Genmab BV $2,340.00 03/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. No dispute reported 06/30/2026 1235937502
Principal investigator 1 Genmab BV $2,600.00 03/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. No dispute reported 06/30/2026 1235937506
Principal investigator 1 Genmab BV $520.00 03/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. No dispute reported 06/30/2026 1235937510
Principal investigator 1 Genmab BV $3,200.00 03/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. No dispute reported 06/30/2026 1235937512
Principal investigator 1 Genmab BV $2,600.00 03/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. No dispute reported 06/30/2026 1235937516
Principal investigator 1 Genmab BV $1,200.00 03/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. No dispute reported 06/30/2026 1235937520
Principal investigator 1 Genmab BV $1,300.00 03/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. No dispute reported 06/30/2026 1235937523
Principal investigator 1 Genmab BV $2,600.00 03/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. No dispute reported 06/30/2026 1235937526
Principal investigator 1 Genmab BV $2,600.00 03/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. No dispute reported 06/30/2026 1235937529
Principal investigator 1 Genmab BV $3,240.00 03/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
Safety and Efficacy of GEN3009 (DuoHexaBody-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts. No dispute reported 06/30/2026 1235937533
Principal investigator 1 ABBVIE INC. $1,040.00 02/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202454069
Principal investigator 1 ABBVIE INC. $1,040.00 02/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202454087
Principal investigator 1 BeiGene USA, Inc. $9,516.00 02/25/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190324572
Principal investigator 1 ABBVIE INC. $2,080.00 02/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202453581
Principal investigator 1 ABBVIE INC. $325.00 02/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202453187
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $390.00 02/19/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804220
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $975.00 02/19/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804222
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $780.00 02/18/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184154590
Principal investigator 1 ABBVIE INC. $187.20 02/13/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202451397
Principal investigator 1 ABBVIE INC. $650.00 02/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202450730
Principal investigator 1 ABBVIE INC. $780.00 02/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202450734
Principal investigator 1 ABBVIE INC. $2,080.00 02/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA CANCER CENTER
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202450739
Principal investigator 1 ABBVIE INC. $52.00 02/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202450840
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 02/10/2025 Non-covered Recipient Entity
The University of Arizona
Brightline-4 No dispute reported 06/30/2026 1220804240
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,850.00 02/10/2025 Non-covered Recipient Entity
The University of Arizona
Brightline-4 No dispute reported 06/30/2026 1220804242
Principal investigator 1 ABBVIE INC. $2,283.79 02/06/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202448879
Principal investigator 1 ABBVIE INC. $975.00 02/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202445361
Principal investigator 1 ABBVIE INC. $780.00 02/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202445513
Principal investigator 1 ABBVIE INC. $1,105.00 02/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202446597
Principal investigator 1 ABBVIE INC. $2,119.00 02/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202443648
Principal investigator 1 BeiGene USA, Inc. $928.00 01/28/2025 Non-covered Recipient Entity
University of Arizona
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies No dispute reported 06/30/2026 1190325866
Principal investigator 1 ABBVIE INC. $3,499.65 01/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
M20-638 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1) No dispute reported 06/30/2026 1202441286
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $877.50 01/27/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804218
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,170.00 01/24/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804210
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $390.00 01/24/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804212
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,950.00 01/24/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804214
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $780.00 01/24/2025 Non-covered Recipient Entity
The University of Arizona
Phase II/III Brigimadlin in 1st L DD Liposarcoma No dispute reported 06/30/2026 1220804216
Principal investigator 1 ABBVIE INC. $2,080.00 01/16/2025 Non-covered Recipient Entity
THE UNIVERSITY OF ARIZONA
M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202439433
Principal investigator 1 Epizyme, Inc. $250.00 01/09/2025 Non-covered Recipient Entity
Banner University Cancer Center
Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study No dispute reported 06/30/2026 1184284530